Eurofins Scientific SE

ERF: XPAR (FRA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
€53.00DnngnyNhfgmrhwg

Eurofins Scientific Earnings: Maintaining Fair Value Estimate as COVID-19-Related Declines Absorbed

Narrow-moat Eurofins posted solid first-quarter results with strong revenue growth despite the loss of COVID-19-related sales. Macroeconomic pressures across the industry may favor the firm once the dust settles, particularly in food, feed, and environmental testing, where it holds the market lead. We are maintaining our fair value estimate of $80 per share.

Sponsor Center